Elon Musk's Neuralink is experiencing a surge in its valuation, reportedly reaching $3.5 billion after its first human trial. This increase has prompted some staff members to prepare for selling their stock in the brain implant company. Recent reports indicate that investors on private exchanges have been paying a premium of 84% to 137% for shares in the company, reflecting heightened interest and speculation about a potential initial public offering (IPO). The developments come amid ongoing discussions about the future of brain-computer interface technologies, with Neuralink's approach involving surgical implantation, contrasting with methods used by competitors such as Synchron.